Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Time–kill curves of M. abscessus CIP

Published byMarilyn Richards Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Time–kill curves of M. abscessus CIP"— Presentation transcript:

1 Figure 1. Time–kill curves of M. abscessus CIP 104536
Figure 1. Time–kill curves of M. abscessus CIP (a) Dose–response of M. abscessus CIP against a ... Figure 1. Time–kill curves of M. abscessus CIP (a) Dose–response of M. abscessus CIP against a concentration range of bedaquiline (BDQ) in CAMHB; the MIC was 0.25 mg/L. (a) Combination time–kill curves of M. abscessus with bedaquiline and clofazimine (CZM) and in combination in M7H9; MICs were 1 mg/L for bedaquiline and 1 mg/L for clofazimine. (c) Percentage of the 3×MIC bedaquiline-resistant population of (b). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 10 January 2019, Pages 935–943, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Time–kill curves of M. avium ATCC 700898
Figure 2. Time–kill curves of M. avium ATCC (a) Dose–response of M. avium ATCC against a concentration ... Figure 2. Time–kill curves of M. avium ATCC (a) Dose–response of M. avium ATCC against a concentration range of bedaquiline (BDQ) in CAMHB; the MIC was 0.06 mg/L. (b) Combination time–kill curves of M. avium with bedaquiline and clarithromycin (CLR) and in combination in CAMHB; MICs were 0.06 mg/L for bedaquiline and 2 mg/L for clarithromycin. (c) Percentage of the 3×MIC clarithromycin-resistant population of (b). (d) Percentage of the 3×MIC bedaquiline-resistant population of (b). (e) Combination time–kill curves of M. avium with bedaquiline and clofazimine (CZM) and in combination in M7H9; MICs were 0.25 mg/L for bedaquiline and 0.25 mg/L for clofazimine. (f) Percentage of the 3×MIC bedaquiline-resistant population of (e). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 10 January 2019, Pages 935–943, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Fitted concentration–response curves of M
Figure 3. Fitted concentration–response curves of M. abscessus (a) and M. avium (b) with bedaquiline. (a) Curve fitting ... Figure 3. Fitted concentration–response curves of M. abscessus (a) and M. avium (b) with bedaquiline. (a) Curve fitting of M. abscessus dose–response against bedaquiline. E<sub>max</sub> was determined to be log<sub>10</sub> cfu/mL×day, EC<sub>50</sub> is 2.45×MIC and the Hill slope was (b) Curve fitting of M. avium dose–response against bedaquiline. E<sub>max</sub> was determined to be log<sub>10</sub> cfu/mL×day, EC<sub>50</sub> is 0.31×MIC and the Hill slope was 1.73. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 10 January 2019, Pages 935–943, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Time–kill curves of M. abscessus CIP"

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.

Fig. 1. Relative potency ratios of 13 active ingredients used against a fall armyworm population collected in Puerto ... Fig. 1. Relative potency ratios.
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
Figure 1. SpeI-PFGE dendrogram comparing P

Figure 1. SpeI-PFGE dendrogram comparing P
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Similar presentations

Ads by Google